ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 001,80
-0,48%
Dow Jones
38 798,99
-0,22%
DAX
18 557,27
-0,48%
Brent Oil
79,395
0,00%
Bitcoin
69 352,23
0,03%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Leap Therapeutics Inc (LPTX)

  7. Leap Therapeutics Inc (LPTX) Actualités

LPTX

Leap Therapeutics (LPTX)

Leap Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:LPTX
DateHeureSourceTitreSymboleSociété
24/05/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:LPTXLeap Therapeutics Inc
23/05/202422h25Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:LPTXLeap Therapeutics Inc
13/05/202413h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPTXLeap Therapeutics Inc
13/05/202413h00PR Newswire (US)Leap Therapeutics Reports First Quarter 2024 Financial ResultsNASDAQ:LPTXLeap Therapeutics Inc
13/05/202412h50Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LPTXLeap Therapeutics Inc
10/05/202423h01Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:LPTXLeap Therapeutics Inc
11/04/202414h30PR Newswire (US)Leap Therapeutics Announces $40 Million Private PlacementNASDAQ:LPTXLeap Therapeutics Inc
18/03/202412h00PR Newswire (US)Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:LPTXLeap Therapeutics Inc
01/02/202403h36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LPTXLeap Therapeutics Inc
26/01/202423h21Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:LPTXLeap Therapeutics Inc
16/01/202423h05PR Newswire (US)Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers SymposiumNASDAQ:LPTXLeap Therapeutics Inc
03/01/202413h00PR Newswire (US)Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:LPTXLeap Therapeutics Inc
02/01/202413h00PR Newswire (US)Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer PatientsNASDAQ:LPTXLeap Therapeutics Inc
11/12/202322h05PR Newswire (US)Leap Therapeutics to Present New Data from Part A of the DeFianCe Study of DKN-01 Plus Bevacizumab and Chemotherapy in Colorectal Cancer Patients at the 2024 ASCO Gastrointestinal Cancers SymposiumNASDAQ:LPTXLeap Therapeutics Inc
21/11/202313h00PR Newswire (US)Leap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare ConferenceNASDAQ:LPTXLeap Therapeutics Inc
13/11/202313h00PR Newswire (US)Leap Therapeutics Reports Third Quarter 2023 Financial ResultsNASDAQ:LPTXLeap Therapeutics Inc
05/09/202313h00PR Newswire (US)Leap Therapeutics to Participate at Upcoming Investor ConferencesNASDAQ:LPTXLeap Therapeutics Inc
14/08/202313h00PR Newswire (US)Leap Therapeutics Reports Second Quarter 2023 Financial ResultsNASDAQ:LPTXLeap Therapeutics Inc
12/07/202313h00PR Newswire (US)Leap Therapeutics Announces Initiation of Randomized Controlled Part B of the DeFianCe Study of DKN-01 in Colorectal Cancer PatientsNASDAQ:LPTXLeap Therapeutics Inc
20/06/202318h30PR Newswire (US)Leap Therapeutics Announces Reverse Stock SplitNASDAQ:LPTXLeap Therapeutics Inc
15/06/202312h26Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:LPTXLeap Therapeutics Inc
14/06/202322h32Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:LPTXLeap Therapeutics Inc
09/06/202322h11Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3/a)NASDAQ:LPTXLeap Therapeutics Inc
25/05/202323h19Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:LPTXLeap Therapeutics Inc
25/05/202323h10PR Newswire (US)Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual MeetingNASDAQ:LPTXLeap Therapeutics Inc
15/05/202313h07Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:LPTXLeap Therapeutics Inc
15/05/202313h00PR Newswire (US)Leap Therapeutics Reports First Quarter 2023 Financial ResultsNASDAQ:LPTXLeap Therapeutics Inc
28/04/202322h23Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:LPTXLeap Therapeutics Inc
28/04/202322h21Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:LPTXLeap Therapeutics Inc
21/04/202323h13Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:LPTXLeap Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:LPTX

Dernières Valeurs Consultées

NASDAQ
FIUWDX
Smid High Dividend Portf...
BIT
UC2XVD
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés